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Abstract 
DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho 
GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse 
prognostic effect in acute myeloid leukemia (AML). We first analyzed data of 85 AML patients who 
were treated with chemotherapy and had available DOCK1 to DOCK11 expression information 
and found that DOCK1 and DOCK2 had prognostic significance in AML. In view of the known 
prognosis of DOCK1 in AML, we then explored the prognostic role of DOCK2. One hundred 
fifty-six AML patients with DOCK2 expression data were extracted from The Cancer Genome 
Atlas (TCGA) database and enrolled in this study. Patients were divided based on treatment 
modality into the chemotherapy group and the allogeneic hematopoietic stem cell transplant 
(allo-HSCT) group. Each group was divided into two groups by the median expression levels of 
DOCK2. In the chemotherapy group, high DOCK2 expression was associated with longer 
event-free survival (EFS, P=0.001) and overall survival (OS, P=0.007). In the allo-HSCT group, EFS 
and OS were not significantly different between high and low DOCK2 expression groups. 
Multivariate analysis showed that high DOCK2 expression was an independent favorable prognostic 
factor for both EFS and OS in all patients (all P<0.05). In conclusion, our results indicated that high 
DOCK2 expression, in contrast to DOCK1, conferred good prognosis in AML. 
Key words: acute myeloid leukemia; DOCK2; allogeneic hematopoietic stem cell transplantation; chemotherapy; 
prognosis 
Introduction 
Genetic abnormality is not only the pathogenic 
basis of acute myeloid leukemia (AML) [1] but also has 
important prognostic implications. For example, 
NPM1 mutations and double CEBPA mutations are 
associated with favorable prognosis in cytogenetically 
normal AML (CN-AML) [2, 3], while DNMT3A and 
WT1 mutations are adverse prognostic factors [4, 5]. 








including DOCK1 to DOCK11 proteins, are 
evolutionarily conserved guanine nucleotide 
exchange factors (GEF) for the Rho GTPases Rac. It is 
involved in various pathologies including cancers, 
immune disorders, and central nervous system 
diseases [6]. For instance, high DOCK1 expression is an 
unfavorable prognostic marker in breast cancer and 
ovarian cancer [7,8], and it induces migration and 
invasion of malignant cells in lung and brain cancer [9, 
10]. Fukui Y et al found that DOCK2 is only expressed 
in hematopoietic tissues [11]. In addition, DOCK2 is 
also associated with the development of various 
cancers [12]. 
Previous study has shown that high DOCK1 
expression conferred poor prognosis in AML [13], but 
the prognosis value of the other DOCK family 
members in AML is unclear. We screened all the 
DOCK family members and found that DOCK2 also 
had independent prognostic significance in AML. 
Materials and Methods 
Patients 
From The Cancer Genome Atlas (TCGA) 
database (https://cancergenome.nih.gov/), 156 AML 
patients with DOCK2 expression data were enrolled 
in this study [14]. All patients were between ages 18 
and 88, registered between November 2001 and 
March 2010, were selected from a set of more than 400 
samples to reflect a realworld distribution of 
subtypes. Eighty-five patients were treated with 
chemotherapy alone, and other 71 received 
allo-HSCT. Patients treated with chemotherapy alone 
were defined as the chemotherapy group; patients 
who underwent allo-HSCT were defined as the 
allo-HSCT group. Then, each group was divided into 
two subgroups by the respective median DOCK2 
expression levels. All clinical and molecular 
information including DOCK2 expression levels were 
publicly accessible from the TCGA website. All 
patients provided written informed consent and the 
research was approved by the Human Research Ethics 
Committee of Washington University. Primary 
endpoints were event-free survival (EFS) and overall 
survival (OS). EFS was defined as the time from 
diagnosis to removal from the study due to the 
absence of complete remission, relapse or death or 
was censored at the last follow-up. OS was defined as 
the time from diagnosis to death or was censored at 
the last follow-up. 
Statistical Analysis 
The clinical and molecular characteristics of 
patients were summarized using descriptive statistics. 
The Mann-Whitney U test and the chi-square test 
were used to compare continuous and categorical 
data, respectively. EFS and OS were estimated with 
the Kaplan-Meier method and compared using the 
log-rank test. Cox proportional hazard model was 
constructed for EFS and OS to identify possible 
prognostic factors among the clinical and molecular 
variables. All statistical analyses were performed by 
SPSS software 20.0 and GraphPad Prism software 5.0. 
For all statistical analyses, P-values were two-sided 
and P<0.05 was considered significant.  
Results 
Comparison of EFS and OS between different 
expression levels of DOCK1-11 
To assess the prognostic significance of DOCK 
family in AML, EFS and OS patients with high and 
low expression groups of each DOCK family proteins 
were compared (Table 1). The results showed that 
DOCK1 was an adverse prognostic factor and DOCK2 
was a favorable prognostic factor in AML. However, 
other DOCK members had no effect on EFS and OS.  
 
Table 1. Comparison of EFS and OS between different expression levels of Dock1-11 based on chemotherapy. 
Variables EFS  OS 
χ2 P-value  χ2 P-value 
Dock1 (high vs. low) 14.908 0.000  14.343 0.000 
Dock2(high vs. low) 13.331 0.000  11.748 0.001 
Dock3 (high vs. low) 0.030 0.863  0.000 0.999 
Dock4(high vs. low) 1.598 0.206  1.658 0.198 
Dock5(high vs. low) 0.153 0.695  0.021 0.884 
Dock6(high vs. low) 0.930 0.335  0.312 0.576 
Dock7 (high vs. low) 0.552 0.457  1.261 0.262 
Dock8(high vs. low) 0.288 0.591  0.419 0.518 
Dock9(high vs. low) 0.170 0.680  0.497 0.481 
Dock10(high vs. low) 0.011 0.916  0.009 0.923 
Dock11(high vs. low) 0.054 0.817  0.002 0.968 
Abbreviations: EFS, event-free survival; OS, overall survival. 
 
 




Table 2. Clinical and molecular characteristics of patients according to DOCK2 levels 
Characteristics 
 
Chemotherapy group  Allo-HSCT group 
High DOCK2 
(n = 42) 
Low DOCK2 
(n = 43) 
P  High DOCK2 
(n = 35) 
Low DOCK2 
(n = 36) 
P 
Age/years, median (range) 66.5 (22-77) 66 (33-88) 0.324*  51 (22-69) 52.5 (18-72) 0.890* 
Age group/n (%)   0.311§    0.205§ 
< 60 years 15 (35.7) 11 (25.6)   28 (80.0) 24 (66.7)  
≥ 60 years 27 (64.3) 32 (74.4)   7 (20.0) 12 (33.3)  
Gender/n (%)   0.591§    0.288§ 
Male 21 (50.0) 24 (55.8)   18 (51.4) 23 (63.9)  
Female 21 (50.0) 19 (44.2)   17 (48.6) 13 (36.1)  
WBC/×109/L, median (range) 15.2(1.0-171.9) 12.3(0.7-297.4) 0.329*  30.9(1.2-223.8) 27.7(0.6-90.4) 0.200* 
BM blast/%, median (range) 71 (30-97) 74 (32-99) 0.379*  71 (34-100) 70 (30-97) 0.809* 
PB blast/%, median (range) 23 (0-91) 25 (0-98) 0.972*  48 (0-96) 53 (0-90) 0.801* 
FAB subtypes/n(%)        
M0 4 (9.5) 3 (7.0) 0.713§  3 (8.6) 6 (16.7) 0.478§ 
M1 7 (16.7) 13 (30.2) 0.140§  14 (40.0) 9 (25.0) 0.177§ 
M2 12 (28.6) 9 (20.9) 0.414§  8 (22.9) 10 (27.8) 0.634§ 
M3 0 (0.0) 0 (0.0)   0 (0.0) 1 (2.8) 1.000§ 
M4 11 (26.2) 9 (20.9) 0.568§  8 (22.9) 5 (13.9) 0.329§ 
M5 7 (16.7) 6 (14.0) 0.728§  1 (2.9) 3 (8.3) 0.614§ 
M6 1 (2.4) 0 (0.0) 0.494§  0 (0.0) 1 (2.8) 1.000§ 
M7 0 (0.0) 2 (4.7) 0.494§  0 (0.0) 1 (1.4) 1.000§ 
Karyotype/n(%)        
Normal 21 (50.0) 19 (44.2) 0.591§  11 (29.7) 23 (62.2) 0.005§ 
Complex 3 (7.1) 9 (20.9) 0.117§  7 (18.9) 5 (13.5) 0.528§ 
inv(16)/CBFβ-MYH11 6 (14.3) 0 (0.0) 0.012§  5 (13.5) 0 (0.0) 0.054§ 
11q23/MLL 0 (0.0) 3 (7.0) 0.241§  2 (5.4) 1 (2.7) 1.000§ 
t(15;17)/PML-RARA 0 (0.0) 0 (0.0)   1 (2.7) 1 (2.7) 1.000§ 
t(9;22)/BCR-ABL1 0 (0.0) 1 (2.3) 1.000§  2 (5.4) 0 (0.0) 0.493§ 
t(8;21)/RUNX1-RUNX1T1 4 (9.5) 2 (4.7) 0.433§  0 (0.0) 1 (2.7) 1.000§ 
Others 8 (19.0) 9 (20.9) 0.828§  4 (10.8) 2 (5.4) 0.674§ 
Risk/n(%)        
Good 10 (23.8) 2 (4.7) 0.014§  5 (14.3) 2 (5.6) 0.260§ 
Intermediate 26 (61.9) 20 (46.5) 0.154§  23 (65.7) 17 (47.2) 0.116§ 
Poor 6 (14.3) 19 (44.2) 0.002§  6 (17.1) 17 (47.2) 0.007§ 
FLT3-ITD/n(%)   0.366§    0.730§ 
Presence 9 (21.4) 6 (14.0)   9 (25.7) 8 (22.2)  
Absence 33 (78.6) 37 (86.0)   29 (78.4) 28 (75.7)  
NPM1/n(%)   0.440§    0.246§ 
Mutation 15 (35.7) 12 (27.9)   11 (31.4) 7 (19.4)  
Wildtype 27 (64.3) 31 (72.1)   24 (68.6) 29 (80.6)  
CEBPA/n(%)   0.557§    0.033§ 
Single mutation 1 (2.4) 2 (4.7)   4 (11.4) 1 (2.8)  
Double mutation 0 (0.0) 0 (0.0)   3 (8.6) 0 (0.0)  
Wild type 41 (97.6) 41 (95.3)   28 (80.0) 35 (97.2)  
DNMT3A/n(%)   0.859§    0.044§ 
Mutation 11 (26.2) 12 (27.9)   12 (34.3) 5 (13.9)  
Wildtype 31 (73.8) 31 (72.1)   23 (65.7) 31 (86.1)  
IDH1/IDH2/n(%)   0.366§    0.730§ 
Mutation 9 (21.4) 6 (14.0)   9 (25.7) 8 (22.2)  
Wildtype 33 (78.6) 37 (86.0)   26 (74.3) 28 (77.8)  
RUNX1/n(%)   0.156§    0.260§ 
Mutation 6 (14.3) 2 (4.7)   2 (5.7) 6 (16.7)  
Wildtype 36 (85.7) 41 (95.3)   33 (94.3) 30 (83.3)  
WT1/n(%)   1.000§    0.478§ 
Mutation 1 (2.4) 1 (2.3)   5 (14.3) 3 (8.3)  
Wildtype 41 (97.6) 42 (97.7)   30 (85.7) 33 (91.7)  
MLL-PTD/n(%)   0.360§    0.614§ 
Presence 1 (2.4) 4 (9.3)   1 (2.9) 3 (8.3)  
Absence 41 (97.6) 39 (90.7)   34 (97.1) 33 (91.7)  
NRAS/KRAS/n(%)   0.505§    0.710§ 
Mutation 7 (16.7) 5 (11.6)   4 (11.4) 3 (8.3)  
Wildtype 35 (83.3) 38 (88.4)   31 (88.6) 33 (91.7)  
TET2/n(%)   0.778§    1.000§ 
Mutation 5 (11.9) 6 (14.0)   2 (5.7) 2 (5.6)  
Wildtype 37 (88.1) 37 (86.0)   33 (94.3) 34 (94.4)  
TP53/n(%)   0.049§    0.115§ 
Mutation 2 (4.8) 9 (20.9)   0 (0.0) 4 (11.1)  






Chemotherapy group  Allo-HSCT group 
High DOCK2 
(n = 42) 
Low DOCK2 
(n = 43) 
P  High DOCK2 
(n = 35) 
Low DOCK2 
(n = 36) 
P 
Wildtype 40 (95.2) 34 (79.1)   35 (100.0) 32 (88.9)  
Relapse/n(%)   0.227§    0.614§ 
Yes 18 (42.9) 13 (30.2)   25 (71.4) 23 (63.9)  
No 24 (57.1) 30 (69.8)   10 (28.6) 13 (36.1)  
Abbreviations: WBC: white blood cell; BM: bone marrow; PB: peripheral blood; FAB: French American British. 
*denotes Mann-Whitney U test; §denotes chi-square test. 
 
 
Figure 1. Kaplan-Meier curves of EFS and OS in the chemotherapy and allo-HSCT groups. (A, B) In the chemotherapy group, high DOCK2 expressers had longer 
EFS and OS than low expressers. (C, D) EFS and OS were not significantly different between high and low DOCK2 expression subgroups in the allo-HSCT group. 
 
Association between DOCK2 expression and 
patient’s characteristics 
Comparison of clinical and molecular 
characteristics between different expression 
subgroups within chemotherapy and allo-HSCT 
groups were summarized in Table 2. In the 
chemotherapy group, high DOCK2 expression group 
had more good-risk patients (P=0.014), fewer 
poor-risk patients (P=0.002) and less TP53mutations 
(P=0.049) than low expression group. Six patients 
among the low expression group harbored 
CBFβ-MYH11, which was not found in the high 
expression group (P=0.012). No significant difference 
was found in age, sex distribution, peripheral white 
blood cell (WBC) count and bone marrow blast (BM) 
percentage at diagnosis, French-American-British 
(FAB) classification, frequency of other recurrent 
genetic mutations (FLT3-ITD, NPM1, CEBPA, 
IDH1/IDH2, RUNX1, MLL-PTD, NRAS/KRAS, TET2, 
WT1 and TP53), or relapse rate between the high and 
low expression subgroups. 
In the allo-HSCT group, high DOCK2 expression 
group had fewer poor-risk patients (P=0.007), fewer 
normal karyotype patients (P=0.005), more CEBPA 
(P=0.033) and DNMT3A mutations (P=0.044) than the 
low expression group. No significant difference was 
found in age, sex distribution, BM blasts, FAB 
classification, frequent AML mutations (FLT3-ITD, 
NPM1, IDH1/IDH2, RUNX1, MLL-PTD, 
NRAS/KRAS, TET2, WT1 and TP53), or relapse rate 
between two subgroups. 
Prognostic value of DOCK2 in AML 
In the chemotherapy group, high DOCK2 
expressers had longer EFS and OS (all P<0.001; Figure 
1A and 1B) than low expressers, but survival was not 
significantly different between DOCK2 high and low 
expression subgroups in the allo-HSCT group (Figure 
1C and 1D). 
We chose DOCK2 expression levels (low vs. 
high), therapy method (chemotherapy vs. 




allo-HSCT), age (<60 vs. ≥60 years), WBC counts 
(<20×109/L vs. ≥20×109/L), FLT3-ITD (positive vs. 
negative) and common AML mutations (NPM1, 
DNMT3A, IDH1/IDH2, RUNX1, WT1, CEBPA and 
TP53, mutated vs.wild) to construct multivariate 
analysis of EFS and OS.  
In the chemotherapy group, multivariate 
analysis showed that age ≥60 years and TP53 
mutations were independent risk factors for EFS and 
OS (all P<0.05), and high DOCK2 expression was an 
independent favorable factor for EFS and OS (all 
P<0.05, Table 3). In the allo-HSCT group, multivariate 
analysis showed that FLT3-ITD was an independent 
risk factor for EFS and OS (all P<0.05). WBC counts 
≥20×109/L and WT1 mutations were independent 
risk factors for EFS. Mutations in RUNX1 and TP53 
were independent risk factors for OS (all P<0.05, Table 
4). 
In all patients, multivariate analysis showed that 
high DOCK2 expression and allo-HSCT were 
independent favorable factors for EFS and OS (all 
P<0.05). Age ≥60 years, WBC counts ≥20×109/L and 
mutations in DNMT3A, RUNX1 and TP53 were 
independent risk factors for EFS and OS (all P<0.05, 
Table 5). 
Correlation analysis of DOCK2 expression and 
genome-wide microRNA and gene expression 
profile 
In order to further evaluate the role of DOCK2 in 
AML, we obtained DOCK2-associated gene 
expression profiles and mircroRNA from TCGA 
database through high-throughput sequencing. There 
were 907 genes were positively associated with 
DOCK2 expression, and 9712 genes were negatively 
associated with DOCK2 expression (P<0.05, fold 
change=1.5, Figure. 2A). Then, we identified 50 
up-regulated and 86 down-regulated microRNAs that 
were significantly correlated with DOCK2 expression 
(P<0.05, fold change=1.5, Figure. 2B). Furthermore, 
gene ontology (GO) enrichment analysis suggested 
that the genes related to DOCK2 expression were 
mainly concentrated in "diencephalon development", 
"adenohypophysis development", "axon guidance", 
"neuron projection guidance", "hypothalamus 
development", "limbic system development", 
"neurotrophin TRK receptor signaling pathway", 
"neurotrophin signaling pathway", "appendage 





Figure 2. Genome-wide gene/microRNA expression profiles and cell signaling pathways associated with DOCK2 expression. (A) Volcano plot of differential 
gene expression. Up-regulated and down-regulated genes were labeled with red and green dots, respectively. (B) Volcano plot of differential microRNA expression. Up-regulated 
and down-regulated microRNAs were labeled with red and green dots, respectively. (C) Gene ontology (GO) enrichment analysis of genes related to DOCK2 expression. 
Table 3. Multivariate analyses for EFS and OS based on chemotherapy 
Variables EFS  OS 
HR (95%CI) P-value  HR (95%CI) P-value 
DOCK2 (high vs. low) 2.301 (1.381-3.835) 0.001  1.974 (1.201-3.245) 0.007 
Age (< 60 v. ≥ 60 years) 2.909 (1.550-5.460) 0.001  2.582 (1.355-4.918) 0.004 
WBC (<20 vs. ≥20×109/L) 1.382 (0.777-2.457) 0.270  1.263 (0.719-2.220) 0.416 
NPM1,mutated v wild type 0.653 (0.352-1.210) 0.175  0.813 (0.439-1.504) 0.509 
DNMT3A, mutated v wild type 0.674 (0.375-1.211) 0.187  0.631 (0.357-1.117) 0.114 
FLT3-ITD, presence v absence 0.801 (0.411-1.558) 0.512  0.974 (0.495-1.916) 0.939 
IDH1/IDH2, mutated v wild typemutated v wild type 1.077 (0.555-2.089) 0.827  1.106 (0.560-2.185) 0.772 
RUNX1, mutated v wild type 0.508 (0.218-1.185) 0.117  0.500 (0.214-1.168) 0.109 
WT1, mutated v wild type 0.638 (0.134-3.041) 0.573  1.094 (0.134-8.929) 0.933 
CEBPA, mutated v wild type 0.471 (0.139-1.596) 0.226  0.461 (0.136-1.567) 0.215 
TP53, mutated v wild type 0.351 (0.154-0.801) 0.013  0.414 (0.184-0.933) 0.033 
Abbreviations: EFS: Event-free survival; OS: Overall survival; WBC: white blood cell. 
 




Table 4. Multivariate analyses for EFS and OS based on allo-HSCT. 
Variables EFS  OS 
HR (95%CI) P-value  HR (95%CI) P-value 
DOCK2 (high vs. low) 1.741 (0.921-3.294) 0.088  1.386 (0.705-2.725) 0.344 
Age (< 60 v. ≥ 60 years) 0.869 (0.453-1.670) 0.674  1.174 (0.600-2.299) 0.639 
WBC (<20 vs. ≥20×109/L) 2.151 (1.127-4.105) 0.020  1.339 (0.687-2.612) 0.391 
NPM1,mutated v wild type 1.878 (0.885-3.984) 0.101  1.476 (0.621-3.507) 0.378 
DNMT3A, mutated v wild type 0.711 (0.344-1.468) 0.356  0.553 (0.258-1.183) 0.127 
FLT3-ITD, presencevabsence 0.407 (0.201-0.826) 0.013  0.451 (0.206-0.990) 0.047 
IDH1/IDH2, mutated v wild typemutated v wild type 0.800 (0.354-1.806) 0.591  1.058 (0.442-2.529) 0.900 
RUNX1, mutated v wild type 0.822 (0.333-2.030) 0.671  0.386 (0.155-0.958) 0.040 
WT1, mutated v wild type 0.361 (0.137-0.949) 0.039  0.607 (0.239-1.540) 0.293 
CEBPA, mutated v wild type 1.358 (0.502-3.676) 0.547  1.106 (0.402-3.042) 0.846 
TP53, mutated v wild type 0.371 (0.112-1.222) 0.103  0.155 (0.043-0.557) 0.004 
Abbreviations: EFS: Event-free survival; OS: Overall survival; WBC: white blood cell. 
 
Table 5. Multivariate analyses for EFS and OS based on chemotherapy and allo-HSCT. 
Variables EFS  OS 
HR (95%CI) P-value  HR (95%CI) P-value 
DOCK2 (high vs. low) 1.721 (1.175-2.518) 0.005  1.489 (1.012-2.191) 0.044 
Chemotherapy v allo-HSCT 1.599 (1.097-2.330) 0.015  1.946 (1.301-2.910) 0.001 
Age (< 60 vs. ≥ 60 years) 1.664 (1.107-2.500) 0.014  1.957 (1.270-3.016) 0.002 
WBC (<20 vs. ≥20×109/L) 1.649 (1.103-2.465) 0.015  1.331 (0.883-2.005) 0.172 
NPM1, mutated v wild type 0.936 (0.593-1.477) 0.777  0.904 (0.559-1.461) 0.680 
DNMT3A, mutated v wild type 0.578 (0.382-0.876) 0.010   0.536 (0.352-0.816) 0.004 
FLT3-ITD, presence v absence 0.781 (0.488-1.252) 0.305  0.888 (0.533-1.478) 0.646 
IDH1/IDH2, mutated v wild typemutated v wild type 1.135 (0.705-1.830) 0.602  1.229 (0.746-2.026) 0.419 
RUNX1, mutated v wild type 0.535 (0.294-0.974) 0.041  0.413 (0.224-0.764) 0.005 
WT1, mutated v wild type 0.612 (0.290-1.288) 0.196  0.762 (0.352-1.650) 0.491 
CEBPA, mutated v wild type 0.580 (0.273-1.232) 0.156  0.671 (0.310-1.453) 0.312 
TP53, mutated v wild type 0.310 (0.160-0.600) 0.001  0.269 (0.137-0.531) 0.000 
Abbreviations: EFS: Event-free survival; OS: Overall survival; WBC: white blood cell. 
 
Discussion 
Our study showed that high DOCK2 expression 
was an independent favorable factor in AML patients 
who underwent chemotherapy alone, but not in 
patients who also underwent allo-HSCT. Consistent 
with previous studies, we also found that high 
DOCK1 expression was an adverse factor in AML [13]. 
Previous researches have demonstrated that 
TP53 mutation and older age were negative 
prognostic factors in AML [15,16], while CBFβ-MYH11 
was associated with favorable prognosis in AML [17]. 
Our study found that in high DOCK2 expression 
patients, there were more good-risk patients, more 
CBFβ-MYH11, and fewer TP53 mutations, suggesting 
that high expression of DOCK2 was more likely to 
co-exist with CBFβ-MYH11 rather than TP53 
mutations. In the chemotherapy group, the survival 
analysis indicated that high DOCK2 expression was a 
favorable factor for EFS and OS, but it not in the 
allo-HSCT group, suggesting that the unfavorable 
effect of low DOCK2 expression might be overcome 
by allo-HSCT. 
DOCK2 has been shown to be a specific Rac 
activator in mature lymphocytes [18]. It is involved in 
neutrophil chemotaxis [19] and NK cells differentiation 
[20]. Previous study found that DOCK2 plays a key role 
in the regulation of cell proliferation in diffuse large B 
cell lymphoma and follicular lymphoma via the ERK 
signaling pathway [21]. Nishihara H et al found that 
DOCK2 is associated with CrkL and regulates Rac1 in 
human leukemia cell lines [22]. Another study revealed 
that DOCK2 regulates CXCR4 signaling in immature 
hematopoietic cells [23]. In the present study, DOCK2 
was associated with "neurotrophin TRK receptor 
signaling pathway", "neurotrophin signaling 
pathway", "appendage morphogenesis". We speculate 
that DOCK2 may play a prognostic role in leukemia 
by interacting with genes in these functional 
pathways. 
A previous study suggested that knocking down 
DOCK2 could sensitize FLT3-ITD leukemic cells to 
cytarabine treatment through the inhibition of Rac1 
pathway [24], whereas in this study, we observed a 
favorable prognostic impact of high DOCK2 
expression in AML patients. This discrepancy might 
be related to the different research objects of the two 
studies, since we did not specifically study AML 
patients with FLT3-ITD. 
DOCK2 may play different roles in the lymphoid 
and myeloid system [21]. This is similar to LEF1. High 
LEF1 expression has been reported as a favorable 
prognostic factor in CN-AML [25], but it is also an 




adverse prognostic factor in adult B-precursor acute 
lymphoblastic leukemia [26]. Low expression of 
DOCK2 is associated with poorer prognosis in 
colorectal cancer [27]. However, the expression level of 
DOCK2 is positively correlated with the proliferation 
rate of CXCL13-induced prostate cancer cells [28]. We 
theorized that DOCK2 had tissue-specific effects in 
different malignancies. 
In summary, two of the 11 members of the 
DOCK family have prognostic significance in AML. 
DOCK1 has adverse prognostic effect and DOCK2 the 
opposite. This finding may further deepen the risk 
stratification system of AML. 
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